Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation. Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial

Giora Weisz, Martin B. Leon, David Holmes, Dean J. Kereiakes, Jeffrey J. Popma, Paul S. Teirstein, Sidney A. Cohen, Hong Wang, Donald E. Cutlip, Jeffrey W. Moses

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Objectives: The aim of this study was to examine the 5-year clinical safety and efficacy outcomes in patients enrolled in the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. Background: The SIRIUS trial was a double-blinded randomized study that demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS). Methods: Patients (n = 1,058) with de novo native coronary artery lesions were randomized to either SES (n = 533) or control BMS (n = 525) and were followed for 5 years. Results: Between 1 and 5 years, additional clinical events were similarly distributed among the sirolimus and control groups. At 5 years, in sirolimus versus control patients, target lesion revascularization was 9.4% versus 24.2% (p < 0.001) and major adverse cardiovascular events and target vessel failure rates were 20.3% versus 33.5% and 22.5% versus 33.5%, respectively (p < 0.0001 for both). There were no significant differences in death, myocardial infarction, and nontarget lesion revascularization. No significant differences were observed in the cumulative incidence of stent thrombosis for sirolimus versus control patients with either protocol-derived (1.0% vs. 0.8%) or Academic Research Consortium definitions (3.9% vs. 4.2%). Conclusions: In patients with noncomplex coronary artery disease, clinical outcomes 5 years after implantation of SES continue to demonstrate significant reduction in the need for repeat revascularization, with similar safety (death and myocardial infarction) compared with BMS, without evidence for either disproportionate late restenosis or late stent thrombosis.

Original languageEnglish (US)
Pages (from-to)1488-1497
Number of pages10
JournalJournal of the American College of Cardiology
Volume53
Issue number17
DOIs
StatePublished - Apr 28 2009

Fingerprint

Sirolimus
Stents
Metals
Thrombosis
Myocardial Infarction
Safety
Coronary Artery Disease
Coronary Vessels
Control Groups
Incidence
Research

Keywords

  • coronary disease
  • diabetes mellitus
  • restenosis
  • stents
  • thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation. Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. / Weisz, Giora; Leon, Martin B.; Holmes, David; Kereiakes, Dean J.; Popma, Jeffrey J.; Teirstein, Paul S.; Cohen, Sidney A.; Wang, Hong; Cutlip, Donald E.; Moses, Jeffrey W.

In: Journal of the American College of Cardiology, Vol. 53, No. 17, 28.04.2009, p. 1488-1497.

Research output: Contribution to journalArticle

Weisz, Giora ; Leon, Martin B. ; Holmes, David ; Kereiakes, Dean J. ; Popma, Jeffrey J. ; Teirstein, Paul S. ; Cohen, Sidney A. ; Wang, Hong ; Cutlip, Donald E. ; Moses, Jeffrey W. / Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation. Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. In: Journal of the American College of Cardiology. 2009 ; Vol. 53, No. 17. pp. 1488-1497.
@article{249f453cf9f64d7daaaa10da3b51e407,
title = "Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation. Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial",
abstract = "Objectives: The aim of this study was to examine the 5-year clinical safety and efficacy outcomes in patients enrolled in the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. Background: The SIRIUS trial was a double-blinded randomized study that demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS). Methods: Patients (n = 1,058) with de novo native coronary artery lesions were randomized to either SES (n = 533) or control BMS (n = 525) and were followed for 5 years. Results: Between 1 and 5 years, additional clinical events were similarly distributed among the sirolimus and control groups. At 5 years, in sirolimus versus control patients, target lesion revascularization was 9.4{\%} versus 24.2{\%} (p < 0.001) and major adverse cardiovascular events and target vessel failure rates were 20.3{\%} versus 33.5{\%} and 22.5{\%} versus 33.5{\%}, respectively (p < 0.0001 for both). There were no significant differences in death, myocardial infarction, and nontarget lesion revascularization. No significant differences were observed in the cumulative incidence of stent thrombosis for sirolimus versus control patients with either protocol-derived (1.0{\%} vs. 0.8{\%}) or Academic Research Consortium definitions (3.9{\%} vs. 4.2{\%}). Conclusions: In patients with noncomplex coronary artery disease, clinical outcomes 5 years after implantation of SES continue to demonstrate significant reduction in the need for repeat revascularization, with similar safety (death and myocardial infarction) compared with BMS, without evidence for either disproportionate late restenosis or late stent thrombosis.",
keywords = "coronary disease, diabetes mellitus, restenosis, stents, thrombosis",
author = "Giora Weisz and Leon, {Martin B.} and David Holmes and Kereiakes, {Dean J.} and Popma, {Jeffrey J.} and Teirstein, {Paul S.} and Cohen, {Sidney A.} and Hong Wang and Cutlip, {Donald E.} and Moses, {Jeffrey W.}",
year = "2009",
month = "4",
day = "28",
doi = "10.1016/j.jacc.2009.01.050",
language = "English (US)",
volume = "53",
pages = "1488--1497",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "17",

}

TY - JOUR

T1 - Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation. Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial

AU - Weisz, Giora

AU - Leon, Martin B.

AU - Holmes, David

AU - Kereiakes, Dean J.

AU - Popma, Jeffrey J.

AU - Teirstein, Paul S.

AU - Cohen, Sidney A.

AU - Wang, Hong

AU - Cutlip, Donald E.

AU - Moses, Jeffrey W.

PY - 2009/4/28

Y1 - 2009/4/28

N2 - Objectives: The aim of this study was to examine the 5-year clinical safety and efficacy outcomes in patients enrolled in the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. Background: The SIRIUS trial was a double-blinded randomized study that demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS). Methods: Patients (n = 1,058) with de novo native coronary artery lesions were randomized to either SES (n = 533) or control BMS (n = 525) and were followed for 5 years. Results: Between 1 and 5 years, additional clinical events were similarly distributed among the sirolimus and control groups. At 5 years, in sirolimus versus control patients, target lesion revascularization was 9.4% versus 24.2% (p < 0.001) and major adverse cardiovascular events and target vessel failure rates were 20.3% versus 33.5% and 22.5% versus 33.5%, respectively (p < 0.0001 for both). There were no significant differences in death, myocardial infarction, and nontarget lesion revascularization. No significant differences were observed in the cumulative incidence of stent thrombosis for sirolimus versus control patients with either protocol-derived (1.0% vs. 0.8%) or Academic Research Consortium definitions (3.9% vs. 4.2%). Conclusions: In patients with noncomplex coronary artery disease, clinical outcomes 5 years after implantation of SES continue to demonstrate significant reduction in the need for repeat revascularization, with similar safety (death and myocardial infarction) compared with BMS, without evidence for either disproportionate late restenosis or late stent thrombosis.

AB - Objectives: The aim of this study was to examine the 5-year clinical safety and efficacy outcomes in patients enrolled in the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. Background: The SIRIUS trial was a double-blinded randomized study that demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS). Methods: Patients (n = 1,058) with de novo native coronary artery lesions were randomized to either SES (n = 533) or control BMS (n = 525) and were followed for 5 years. Results: Between 1 and 5 years, additional clinical events were similarly distributed among the sirolimus and control groups. At 5 years, in sirolimus versus control patients, target lesion revascularization was 9.4% versus 24.2% (p < 0.001) and major adverse cardiovascular events and target vessel failure rates were 20.3% versus 33.5% and 22.5% versus 33.5%, respectively (p < 0.0001 for both). There were no significant differences in death, myocardial infarction, and nontarget lesion revascularization. No significant differences were observed in the cumulative incidence of stent thrombosis for sirolimus versus control patients with either protocol-derived (1.0% vs. 0.8%) or Academic Research Consortium definitions (3.9% vs. 4.2%). Conclusions: In patients with noncomplex coronary artery disease, clinical outcomes 5 years after implantation of SES continue to demonstrate significant reduction in the need for repeat revascularization, with similar safety (death and myocardial infarction) compared with BMS, without evidence for either disproportionate late restenosis or late stent thrombosis.

KW - coronary disease

KW - diabetes mellitus

KW - restenosis

KW - stents

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=64649084378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64649084378&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2009.01.050

DO - 10.1016/j.jacc.2009.01.050

M3 - Article

C2 - 19389558

AN - SCOPUS:64649084378

VL - 53

SP - 1488

EP - 1497

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 17

ER -